DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-7.07%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$393M
AUM Growth
+$393M
(-7.1%)
Cap. Flow
+$17.2M
Cap. Flow
% of AUM
4.37%
Top 10 Holdings %
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$4.95M |
| 2 |
TELA Bio
TELA
|
$4.35M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$2.44M |
| 4 |
Ascendis Pharma
ASND
|
$1.9M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$1.84M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$2.46M |
| 2 |
Aquestive Therapeutics
AQST
|
$1.65M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$1.62M |
| 4 |
Axogen
AXGN
|
$1.47M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$1.22M |
Sector Composition
| 1 | Healthcare | 86.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.25B
| $35.8M | 9.1% |
397,505
-4,000
| -1% | -$360K |
|
2
Stereotaxis
STXS
$246M
| $31.2M | 7.93% |
13,680,554
| – | – |
|
|
3
Revolution Medicines
RVMD
$7.39B
| $27.6M | 7.02% |
631,176
+113,182
| +22% | +$4.95M |
|
4
AtriCure
ATRC
$1.8B
| $19.6M | 4.98% |
641,673
| – | – |
|
5
Merus
MRUS
$5.01B
| $19M | 4.83% |
451,804
+39,231
| +10% | +$1.65M |
|
6
Cytokinetics
CYTK
$5.94B
| $18.7M | 4.76% |
398,100
| – | – |
|
|
7
Ascendis Pharma
ASND
$12.1B
| $14.2M | 3.62% |
103,355
+13,783
| +15% | +$1.9M |
|
|
8
Axogen
AXGN
$723M
| $14M | 3.55% |
846,882
-89,012
| -10% | -$1.47M |
|
9
iShares Biotechnology ETF
IBB
$5.69B
| $13.6M | 3.44% |
102,500
| – | – |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $13.1M | 3.32% |
149,763
+28,000
| +23% | +$2.44M |
|
11
IDEAYA Biosciences
IDYA
$2.23B
| $12.8M | 3.26% |
498,827
+27,417
| +6% | +$705K |
|
12
Xenon Pharmaceuticals
XENE
$3.03B
| $10.7M | 2.73% |
273,739
| – | – |
|
13
Neurocrine Biosciences
NBIX
$14.1B
| $9.78M | 2.48% |
71,615
+2,000
| +3% | +$273K |
|
14
Day One Biopharmaceuticals
DAWN
$758M
| $9.27M | 2.36% |
731,363
-19,000
| -3% | -$241K |
|
15
Biohaven
BHVN
$1.68B
| $8.23M | 2.09% |
220,235
+33,105
| +18% | +$1.24M |
|
16
Tandem Diabetes Care
TNDM
$864M
| $8.04M | 2.04% |
223,208
+19,000
| +9% | +$684K |
|
17
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.17M | 1.82% |
542,002
+15,300
| +3% | +$202K |
|
18
KalVista Pharmaceuticals
KALV
$719M
| $6.87M | 1.75% |
811,678
+88,000
| +12% | +$745K |
|
19
UroGen Pharma
URGN
$904M
| $5.25M | 1.33% |
492,515
+33,600
| +7% | +$358K |
|
20
DexCom
DXCM
$29.1B
| $5.1M | 1.3% |
65,552
| – | – |
|
21
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.02M | 1.28% |
667,000
| – | – |
|
22
Edgewise Therapeutics
EWTX
$1.57B
| $5M | 1.27% |
187,140
-40,766
| -18% | -$1.09M |
|
|
23
TELA Bio
TELA
$68.9M
| $4.35M | 1.11% |
+1,441,029
| New | +$4.35M |
|
24
ProQR Therapeutics
PRQR
$241M
| $4.15M | 1.06% |
1,567,561
+661,979
| +73% | +$1.75M |
|
25
Kura Oncology
KURA
$690M
| $3.91M | 0.99% |
448,368
+40,000
| +10% | +$348K |
|